(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €33.62 | 4.16% | 7.15% |
| LNA SANTE (LNA.PA) | €20.45 | 2.34% | 7.98% |
| IPSEN (IPN.PA) | €110.30 | 1.05% | 17.3% |
| TUBIZE-FIN (TUB.BR) | €105.20 | 0.92% | 4.97% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
4.16% Forward Dividend Yield and 7.15% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing €12.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.15%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BOIRON’s stock is considered to be overbought (>=80).
More news about BOIRON.
2. LNA SANTE (LNA.PA)
2.34% Forward Dividend Yield and 7.98% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.
More news about LNA SANTE.
3. IPSEN (IPN.PA)
1.05% Forward Dividend Yield and 17.3% Return On Equity
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, IPSEN has a trailing twelve months EPS of €7.4.
PE Ratio
IPSEN has a trailing twelve months price to earnings ratio of 14.91. Meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.3%.
More news about IPSEN.
4. TUBIZE-FIN (TUB.BR)
0.92% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.98.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 53.13. Meaning, the purchaser of the share is investing €53.13 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 30, 2024, the estimated forward annual dividend rate is 0.97 and the estimated forward annual dividend yield is 0.92%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €105.20 at 02:30 EST, under its 52-week high of €109.20 and way higher than its 52-week low of €60.80.
More news about TUBIZE-FIN.
